A. Santini

发表

Pharmacodynamics and Pharmacokinetics of AM103, a Novel Inhibitor of 5‐Lipoxygenase‐Activating Protein (FLAP)

D. Lorrain, P. Prasit, J. Evans, 2010, Clinical pharmacology and therapeutics.

N-Acridin-9-yl-butane-1,4-diamine derivatives: high-affinity ligands of the alpha2delta subunit of voltage gated calcium channels.

S. Venkatraman, B. Muñoz, H. Schaffhauser, 2004, Bioorganic & medicinal chemistry letters.

Pharmacological Characterization of 3-[3-tert-Butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic Acid (AM103), a Novel Selective 5-Lipoxygenase-Activating Protein Inhibitor That Reduces Acute and Chronic Inflammation

Jilly F. Evans, D. Lorrain, C. King, 2009, Journal of Pharmacology and Experimental Therapeutics.

Mouse Models of Liver Fibrosis

Andiliy G. Lai, C. King, J. Hutchinson, 2016 .

Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitor.

Jilly F. Evans, C. King, J. Bentley, 2013, British journal of clinical pharmacology.

Pharmacological Blockade of the DP2 Receptor Inhibits Cigarette Smoke-Induced Inflammation, Mucus Cell Metaplasia, and Epithelial Hyperplasia in the Mouse Lung

Jilly F. Evans, D. Lorrain, P. Prasit, 2010, Journal of Pharmacology and Experimental Therapeutics.

5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor.

Jilly F. Evans, D. Lorrain, P. Prasit, 2011, Journal of medicinal chemistry.

Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation.

Jilly F. Evans, D. Lorrain, P. Prasit, 2010, European journal of pharmacology.

5-Lipoxygenase-activating protein inhibitors. Part 3: 3-{3-tert-Butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM643)-A potent FLAP inhibitor suitable for topical administration.

Jilly F. Evans, D. Lorrain, P. Prasit, 2010, Bioorganic & medicinal chemistry letters.

5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)--a potent FLAP inhibitor.

Jilly F. Evans, D. Lorrain, P. Prasit, 2010, Bioorganic & medicinal chemistry letters.

5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).

Jilly F. Evans, D. Lorrain, P. Prasit, 2009, Journal of medicinal chemistry.

Selective Inhibition of Autotaxin Is Efficacious in Mouse Models of Liver Fibrosis

Jilly F. Evans, Andiliy G. Lai, C. King, 2017, The Journal of Pharmacology and Experimental Therapeutics.

Pharmacokinetic and Pharmacodynamic Characterization of an Oral Lysophosphatidic Acid Type 1 Receptor-Selective Antagonist

Jilly F. Evans, D. Lorrain, P. Prasit, 2011, Journal of Pharmacology and Experimental Therapeutics.

Discovery and optimization of a biphenylacetic acid series of prostaglandin D2 receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis.

Jilly F. Evans, D. Lorrain, P. Prasit, 2011, Bioorganic & medicinal chemistry letters.

Pharmacology of AM211, a Potent and Selective Prostaglandin D2 Receptor Type 2 Antagonist That Is Active in Animal Models of Allergic Inflammation

Jilly F. Evans, D. Lorrain, P. Prasit, 2011, Journal of Pharmacology and Experimental Therapeutics.

Sodium [2'-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4'-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): a potent, selective prostaglandin D2 receptor antagonist.

Jilly F. Evans, D. Lorrain, P. Prasit, 2011, Bioorganic & medicinal chemistry letters.

Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.

Jilly F. Evans, D. Lorrain, P. Prasit, 2009, Bioorganic & medicinal chemistry letters.

Overcoming Preclinical Safety Obstacles to Discover (S)-N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (GDC-2394): A Potent and Selective NLRP3 Inhibitor.

Matthew S. Johnson, M. Ultsch, J. Veal, 2022, Journal of medicinal chemistry.

Identification and synthesis of [1,2,4]triazolo[3,4-a]phthalazine derivatives as high-affinity ligands to the α2δ-1 subunit of voltage gated calcium channel

S. Venkatraman, J. Gunzner, B. Muñoz, 2004 .

Synthesis and biological evaluation of 6-aryl-6H-pyrrolo[3,4-d]pyridazine derivatives as high-affinity ligands of the α2δ subunit of voltage-gated calcium channels

Brian T. Campbell, S. Venkatraman, B. Muñoz, 2004 .

Structural Basis for Inhibition of Human Autotaxin by Four Potent Compounds with Distinct Modes of Binding

Jilly F. Evans, J. Hutchinson, Jeffrey M. Schaub, 2015, Molecular Pharmacology.

Structural Basis for Inhibition of Human Autotaxin by Four Potent Compounds with Distinct Modes of Binding s

Jilly F. Evans, J. Hutchinson, G. Bain, 2015 .

Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2).

Jilly F. Evans, Andiliy G. Lai, D. Mackenna, 2017, Journal of medicinal chemistry.

Pharmacology of a Potent and Novel Inhibitor of the NOD-Like Receptor Pyrin Domain-Containing Protein 3 (NLRP3) Inflammasome that Attenuates Development of Nonalcoholic Steatohepatitis and Liver Fibrosis

J. Veal, A. Feldstein, J. Stafford, 2023, The Journal of Pharmacology and Experimental Therapeutics.

Pharmacology of a Potent and Novel Inhibitor of the NOD-like receptor pyrin domain-containing protein 3 (NLRP3) Inflammasome that Attenuates Development of NASH and Liver Fibrosis

J. Veal, A. Feldstein, Christopher Mcbride, 2023 .

A novel, orally active LPA1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin model

D. Lorrain, P. Prasit, T. J. Seiders, 2010, British journal of pharmacology.

Sodium [2'-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4'-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): a potent, selective prostaglandin D2 receptor antagonist.

Jilly F. Evans, D. Lorrain, P. Prasit, 2011, Bioorganic & medicinal chemistry letters.

Pharmacokinetic and Pharmacodynamic Characterization of an Oral Lysophosphatidic Acid Type 1 Receptor-Selective Antagonist

Jilly F. Evans, D. Lorrain, P. Prasit, 2011, Journal of Pharmacology and Experimental Therapeutics.

JT002, a small molecule inhibitor of the NLRP3 inflammasome for the treatment of autoinflammatory disorders

E. Gelfand, J. Veal, A. Joetham, 2023, Scientific reports.